Navegação por autor "Clemens, Sue Ann Costa"
Itens para a visualização no momento 1-13 of 13
-
Antibody evasion by the P.1 strain of SARS-CoV-2
Dejnirattisai, Wanwisa et al. | Data do documento: 2021 -
Efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 lineages circulating in Brazil
Clemens, Sue Ann Costa et al. | Data do documento: 2021 -
Efficacy of the adjuvanted subunit protein COVID-19 vaccine, SCB-2019: a phase 2 and 3 multicentre, double-blind, randomised, placebo-controlled trial
Bravo, Lulu et al. | Data do documento: 2022 -
Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study
Clemens, Sue Ann Costa et al. | Data do documento: 2022 -
Lessons from the pandemic: responding to emerging zoonotic viral diseases—a Keystone Symposia report
Cable, Jennifer et al. | Data do documento: 2022 -
Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, Wanwisa et al. | Data do documento: 2021 -
Pertussis antibodies and vaccination coverage among healthcare professionals in Brazil is inadequate
Cardona, Rita Soares Barbosa et al. | Data do documento: 2023 -
Randomized immunogenicity and safety study of heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine
Clemens, Sue Ann Costa et al. | Data do documento: 2021 -
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum
Liu, Chang et al. | Data do documento: 2021 -
Reduced neutralization of SARS-CoV-2 B.1.617 by vaccine and convalescent serum (preprint)
Liu, Chang et al. | Data do documento: 2021A pesquisa aponta que o soro de pessoas previamente infectadas por outras cepas é menos potente contra esta variante viral. O problema é observado de forma marcante entre os indivíduos anteriormente infectados pela variante ... -
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
Voysey, Merryn et al. | Data do documento: 2021 -
SARS-CoV-2 Omicron-B. 1.1. 529 leads to widespread escape from neutralizing antibody responses
Dejnirattisai, Wanwisa et al. | Data do documento: 2022A Variante de Preocupação Ômicron (B.1.1.529) trouxe uma grande expansão mundial dos contágios pelo SARS-CoV-2, mesmo em países onde a imunização contra o vírus já estava avançada. Para compreender como a coleção de mutações ... -
Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials
Voysey, Merryn et al. | Data do documento: 2021